What Is GLOW 70mg?

GLOW 70mg is a lyophilised triple-peptide research blend formulated by Arma Peptides, combining three well-characterised research compounds in a single vial for comparative in-vitro work. Each vial contains BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg — 70mg of lyophilised powder total, at ≥99% purity across all three components. BPC-157 (CAS 137525-51-0, PubChem CID 9941957) is a synthetic 15-amino-acid peptide, MW 1,419.5 g/mol. TB-500 (CAS 885340-08-9, PubChem CID 62707662) is a synthetic fragment of Thymosin Beta-4, MW 4,963.4 g/mol. GHK-Cu (CAS 49557-75-7) is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with Cu²⁺), MW 340.38 g/mol. All three components are verified by HPLC and mass spectrometry, with results on our Certificate of Analysis page. Supplied for laboratory research use only.

Why These Three Compounds Are Studied Together

The three components of GLOW 70mg are associated with distinct, non-overlapping mechanisms in the published literature, which is why researchers order them as a set rather than individually. BPC-157 has been investigated in the context of VEGFR2 signalling and nitric oxide pathway modulation. TB-500 contains the LKKTET motif associated with G-actin sequestration and cytoskeletal dynamics. GHK-Cu has been studied in gene-expression models and in copper-transport chemistry. Supplying all three in one vial at a fixed, documented ratio removes the weighing and cross-contamination variables that arise when a laboratory blends three separate powders in-house. No combined effect is claimed for this formulation, and the blend itself has not been the subject of published study.

GHK-Cu Component — Literature Profile

GHK-Cu is one of the most extensively published copper-binding tripeptides in cell biology. A review in PMC6073405 surveys the in-vitro and animal literature on this peptide, including reported observations relating to collagen and elastin gene expression, glycosaminoglycan production and antioxidant enzyme activity. These are findings reported in published models and are stated here to indicate why the compound is of research interest. They are not properties of this product, and no outcome is claimed or implied. GHK-Cu is the largest component of this blend at 50mg.

BPC-157 Component — Literature Profile

BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in gastric juice. The published literature, reviewed in PMC8228050, describes work in animal and cell models examining EGR1 expression, collagen deposition and nitric-oxide-system interactions. It is noted in that literature for chemical stability across a broad pH range, which is a practical consideration when formulating multi-peptide preparations. As above, these are reported research findings, not characteristics attributed to this product.

TB-500 Component — Literature Profile

TB-500 is the synthetic active fragment of Thymosin Beta-4. Published preclinical work examines its role in cell motility and cytoskeletal reorganisation, with a current scoping review available in Applied Sciences (2026). It is included in this blend as the third distinct mechanism of interest alongside BPC-157 and GHK-Cu.

Storage & Handling

Store the lyophilised powder at −20°C, protected from light and moisture. Reconstitute with bacteriostatic water or sterile saline immediately before use in your protocol. Once reconstituted, hold at 4°C and use within 28 days. Do not refreeze reconstituted solution. Handle under sterile laboratory conditions by qualified personnel only.

Technical Specifications

Related Research Compounds

• BPC-157 & TB-500 Blend 20mg — two-component blend without GHK-Cu
• GHK-Cu 50mg — isolated copper tripeptide
• GHK-Cu 100mg — higher-quantity GHK-Cu vial
• BPC-157 10mg — isolated, for single-compound protocols
• TB-500 5mg — isolated Thymosin Beta-4 fragment